Omkar Speciality Chemicals Ltd (OSCL) today reported 64.41 per cent jump in net profit at Rs 8.17 crore in the first quarter ended June 30 compared with Rs 4.97 crore in the same period of last fiscal.
Total income in the quarter stood at Rs 90.48 crore, up from Rs 53.51 crore in the same period last year, said the company, engaged in the field of speciality chemicals and Active Pharmaceutical Ingredients (APIs).
Earnings before interest, tax, depreciation and amortisation (EBITDA) in Q1FY16 stood at Rs 17.26 crore, up 98.02 per cent. The EBITDA margin improved from 16.29 per cent in Q1 FY15 to 19.08 per cent in Q1 FY16, a company statement said here.
Earnings per share (EPS) in the April-June period stood at Rs 3.97, up 64.73 per cent from Rs 2.41 in the quarter ended June 30, 2014.
"We have registered a robust increase in our top-line with the commencement of operations of the additional capacity at Chiplun (in Maharashtra).
"We believe traction in sales to continue over the coming quarters with a steady improvement in capacity utilisation. The margins have increased because of higher composition of speciality chemicals and APIs in the total sales," Omkar Speciality Whole-Time Director Omkar Herlekar said.
Mumbai-headquartered, OSCL has nine units in Maharashtra with over 1,100 workforce. The company is fully backward integrated and has an installed capacity of 4,920 MTPA.
The company's product segments include iodine compounds, selenium compounds, intermediates, resolving agents, veterinary growth enhancers and APIs which comprises more than 200 products.
